SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 5.16% Stake in AngioDynamics Inc.
Beneficial Ownership Report
Armistice Capital, LLC and its managing member Steven Boyd have jointly disclosed a beneficial ownership of 5.16% in AngioDynamics Inc.'s common stock, totaling 2,094,000 shares.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed a Schedule 13G.
- The filing indicates beneficial ownership of 2,094,000 shares of AngioDynamics Inc. Common Stock.
- This stake represents 5.16% of the total class of securities outstanding.
- The percentage is based on 40,606,986 shares outstanding as of April 1, 2025, as reported in AngioDynamics Inc.'s 10-Q filed on April 2, 2025.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities.
- The shares are held with shared voting power and shared dispositive power by the reporting persons.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment firm and its principal in a publicly traded company within the medical technology or healthcare sector, specifically AngioDynamics Inc. It does not provide broader industry trends but indicates an investment firm's confidence or strategic interest in the company.
Stakeholder Impact
- Shareholders: The disclosure of a new significant shareholder (Armistice Capital and Steven Boyd) holding 5.16% of the common stock could be viewed positively by some investors as a vote of confidence or a potential catalyst for future engagement, while others might monitor for any activist intentions, though the filing states the stake is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold crossed). |
| 04/01/2025 | Date as of which 40,606,986 shares outstanding were reported in the Issuer's 10-Q. |
| 04/02/2025 | Date AngioDynamics Inc. filed its 10-Q with the SEC, reporting shares outstanding. |
| 05/15/2025 | Date the Schedule 13G was signed and filed by Armistice Capital, LLC and Steven Boyd. |
Keywords
AngioDynamics Inc., ANGI, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.